EGFR and prostate cancer: Among these, compound 1—(E)-2-((3-benzyl-8-methyl-2-oxo-2H-chromen-7-yl)oxy)-N’-(1-(4-bromophenyl)ethylidene)acetohydrazide (Figure 4)—showed notable cytotoxicity against human prostate cancer PC-3 and triple-negative breast cancer MDA-MB-231 cell lines, with IC50 = 3.56 μM and 8.5 μM, respectively, reportedly exceeding the potency of erlotinib (quinazoline-based EGFR tyrosine-kinase inhibitor; non-coumarin) under comparable conditions [24].